Chimerix Inc CMRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.95
- Day Range
- $0.94–1.02
- 52-Week Range
- $0.88–1.57
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $89.63 Mil
- Volume/Avg
- 428,991 / 426,945
Key Statistics
- Price/Earnings (Normalized)
- 20.08
- Price/Sales
- 2,067.03
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 72
- Website
- https://www.chimerix.com
Comparables
Valuation
|
Metric
|
CMRX
|
HLVX
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.08 | — | — |
Price/Book Value | 0.49 | 2.47 | 3.30 |
Price/Sales | 2,067.03 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CMRX
HLVX
ICVX
Financial Strength
|
Metric
|
CMRX
|
HLVX
|
ICVX
|
|---|---|---|---|
Quick Ratio | 8.40 | 10.37 | 17.59 |
Current Ratio | 8.61 | 10.62 | 18.06 |
Interest Coverage | — | −54.72 | — |
Quick Ratio
CMRX
HLVX
ICVX
Profitability
|
Metric
|
CMRX
|
HLVX
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −29.49% | −34.03% | −29.30% |
Return on Equity (Normalized) | −32.10% | −42.52% | −31.87% |
Return on Invested Capital (Normalized) | −36.96% | −38.62% | −34.69% |
Return on Assets
CMRX
HLVX
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xbjkfqxh | Vjnz | $547.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hbtvdrsn | Mzhklt | $105.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Flpgzkcb | Qdsgdl | $103.7 Bil | |
MRNA
| Moderna Inc | Yyzdyxjvc | Fpdd | $46.8 Bil | |
ARGX
| argenx SE ADR | Nrrsjrzq | Xsty | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Ysbrxmdgw | Prcb | $22.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mstcsfqb | Fctzch | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lrzwjknyd | Wtqgbd | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xyssppdhgp | Xmwnlgk | $12.8 Bil | |
INCY
| Incyte Corp | Bwqgclhd | Dsczxv | $12.1 Bil |